GlobeNewswire

Two London ex-Bankers launch first UK regulated Digital Asset Trading Platform and Crypto exchange accessible to Institutional Investors

Dela

LONDON, July 16, 2018 (GLOBE NEWSWIRE) -- UK's first native crypto exchange platform is on its way to become a reality.

Sovren Exchange, a venture founded by a team of London-based banking executives, has announced an Initial Coin Offering (ICO) to begin Q3 of this year. For their launch, Sovren (SVRN) is raising a maximum of 10 Million USD (combination of Equity Funding and its own Sovren Token) to create a hybrid order book and brokerage exchange platform that uses a trading engine supported by Artificial Intelligence (AI) and Robotic Process Automation (RPA).

Sovren will have a fully compliant platform that will support trading in derivates, equities, commodities and securities. The platform will use intelligent automation to address liquidity challenges and a 3rd party custodial service for additional protection with a European Bank.

Sovren is supporting trading between all major crypto assets and fiat currencies like pounds, euros, and dollars, aiming for same day service and low, flat trading fees.

Cryptocurrency exchanges are already immensely profitable. According to the estimates reported by Bloomberg, Tokyo-based Binance alone pulls in more than 3 million USD in fees per day.

Sovren are in the final stages of building the platform with plans to be fully regulated by the UK's Financial Conduct Authority (FCA). It will be the first to do so. There is a strategic focus towards institutional investors and to provide an industrial grade platform that is regulated, compliant and transparent. 

"London is one of the most innovative financial hubs in the world," said Sovren co-founder and CEO Avijeet Jayashekhar. "Building, maintaining and regulating a cryptocurrency exchange here makes a lot of sense. We on the Sovren team have the experience necessary to approach that process from the outset, rather than as an afterthought."

One such team members is Sovren co-founder and CTO Wynand de Jager, who is a member of the British Blockchain Association with over 15 years experience implementing disruptive technology in the financial industry.

"There are a lot of opportunities and possibilities in a decentralized ecosystem, not least of which is making finance more inclusive than it has ever been," said Wynand. "To take part in the current crypto world, however, you need to be quite technical. We want to change that."

To this end, Sovren plans on implementing many of the processes and tech that power modern digital banking.

"The banking business, especially on the retail side, is a very competitive industry. If banks had the kind of customer service crypto exchanges currently have, they wouldn't last very long," said Avijeet. "Most of the technology is there to make the improvements necessary but because of the decentralized nature of blockchain, they need to be implemented in a new way."

Much of that technology revolves around automating processes with the help of artificial intelligence, AI, and Robotic Process Automation, RPA.

"I spent a big part of my career building technology to improve the customer experience in banks and trading platforms like NASDAQ," explained Avijeet. "When AI, Robotic Process Automation and Blockchain started emerging in early 2010, I got deeply involved in building businesses around them."

Sovren plans on implementing AI and RPA to do tasks it has already proven successful at: performing customer service activities, recognizing and analyzing patterns in data to help traders make better decisions, and monitoring trading traffic to detect cyber threats.

"We will deliver customer service using emotionally intelligent chat AI and robotics to automate recurring functions in the front office, and back office such as customer onboarding, compliance, transaction processing, deactivation and activation of accounts and trading and settlement. This will significantly increase processing speed in comparison to most current crypto exchange operations," explained Wynand. "We will of course also have real people overseeing, who will focus on high value tasks that can't be easily solved by robotics."

Customer service teams will be on hand 24/7 to handle high order issues. Sovren also plans on having an around-the-clock Security Operations Center to prevent, detect and respond to threats to the platform.

Top cyber security expert Luke Lynch has joined Sovren to ensure that it is built to the highest standard.

"Good security comes down to being able to recognize and respond to threats quickly," said Luke. "With the aid of machine learning, pattern recognition and neural network, we can shut down attacks before they can have a major impact."

"We want to decentralize the technologies that give institutional investors a leg up," said Avijeet. "That means giving everyone access to algorithms that, for example, measure trend-based strategies that involve moving averages, channel breakouts, price level movements and other technical indicators. AI will also help provide traders with advanced analytics with what is going on in the market."

Creating an exchange platform that can securely automate and process customer transactions with the speed and efficiency found in the banking industry requires a robust architecture that can do much more besides.

Sovren plans on developing applications, such as a payment gateway for merchants, a wallet to store crypto assets, and even a demo platform for customers to practice crypto trading before they embark on the real thing.

Beta releases for applications are expected end of 2018 and into 2019.

Sovren will open up APIs for any developer to use in creating their own applications, and will offer white label solutions to larger institutional investors.

"It is often a mistake to try and build a customized application from scratch for any business especially if the market the business is trying to enter falls outside their development expertise," said Avijeet. "We will be well positioned to save organizations time and money by building it for them."

Needless to say, the vision for the Sovren ecosystem is bigger than a crypto exchange.

"I think it is safe to say it all revolves around making cryptocurrency technology more accessible to the mainstream," said Wynand. "The High Street deserves a greater chance to benefit from the promise of blockchain."

Sovren is currently raising funds through Financial Institutions and traditional venture capitalist funds. Details for Sovren ICO can be found at https://sovren.exchange.

Investment Contact:

Chris Parker
Head of Business Development
Email: privatesale@sovren.exchange

Media Contact:

Natalia Boruch
Head of Media Relation
Email: ico@sovren.exchange

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/26346fad-2ce9-4218-970f-fc0711d34aca




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sovren Exchange via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum